180 related articles for article (PubMed ID: 24886621)
1. The dipeptidyl peptidase-4 inhibitor saxagliptin improves function of circulating pro-angiogenic cells from type 2 diabetic patients.
Poncina N; Albiero M; Menegazzo L; Cappellari R; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2014 May; 13():92. PubMed ID: 24886621
[TBL] [Abstract][Full Text] [Related]
2. Novel repair mechanisms in a renal ischaemia/reperfusion model: Subsequent saxagliptin treatment modulates the pro-angiogenic GLP-1/cAMP/VEGF, ANP/eNOS/NO, SDF-1α/CXCR4, and Kim-1/STAT3/HIF-1α/VEGF/eNOS pathways.
Kamel NM; Abd El Fattah MA; El-Abhar HS; Abdallah DM
Eur J Pharmacol; 2019 Oct; 861():172620. PubMed ID: 31437429
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
Connelly KA; Advani A; Zhang Y; Advani SL; Kabir G; Abadeh A; Desjardins JF; Mitchell M; Thai K; Gilbert RE
J Diabetes; 2016 Jan; 8(1):63-75. PubMed ID: 25565455
[TBL] [Abstract][Full Text] [Related]
4. Exploration of the DPP-4 inhibitors with a focus on saxagliptin.
Shubrook JH; Colucci RA; Schwartz FL
Expert Opin Pharmacother; 2009 Dec; 10(17):2927-34. PubMed ID: 19929711
[TBL] [Abstract][Full Text] [Related]
5. The DPP-4 inhibitor saxagliptin ameliorates ox-LDL-induced endothelial dysfunction by regulating AP-1 and NF-κB.
Ma S; Bai Z; Wu H; Wang W
Eur J Pharmacol; 2019 May; 851():186-193. PubMed ID: 30639312
[TBL] [Abstract][Full Text] [Related]
6. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats.
Uchii M; Kimoto N; Sakai M; Kitayama T; Kunori S
Eur J Pharmacol; 2016 Jul; 783():56-63. PubMed ID: 27063445
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor.
Boulton DW
Clin Pharmacokinet; 2017 Jan; 56(1):11-24. PubMed ID: 27282159
[TBL] [Abstract][Full Text] [Related]
8. Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.
Schwartz SL
Ann Med; 2012 Mar; 44(2):157-69. PubMed ID: 22132773
[TBL] [Abstract][Full Text] [Related]
9. Healthcare Costs Among Adults with Type 2 Diabetes Initiating DPP-4 Inhibitors.
Farr AM; Sheehan JJ; Brouillette M; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2016 Jan; 33(1):68-81. PubMed ID: 26724938
[TBL] [Abstract][Full Text] [Related]
10. Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs.
Saine ME; Carbonari DM; Newcomb CW; Nezamzadeh MS; Haynes K; Roy JA; Cardillo S; Hennessy S; Holick CN; Esposito DB; Gallagher AM; Bhullar H; Strom BL; Lo Re V
BMC Pharmacol Toxicol; 2015 Apr; 16():8. PubMed ID: 25889498
[TBL] [Abstract][Full Text] [Related]
11. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes.
Ott C; Raff U; Schmidt S; Kistner I; Friedrich S; Bramlage P; Harazny JM; Schmieder RE
Cardiovasc Diabetol; 2014 Jan; 13():19. PubMed ID: 24423149
[TBL] [Abstract][Full Text] [Related]
12. Saxagliptin in type 2 diabetes.
Billiones R
Drugs Today (Barc); 2010 Feb; 46(2):101-8. PubMed ID: 20393638
[TBL] [Abstract][Full Text] [Related]
13. Impact of treatment with saxagliptin on glycaemic stability and β-cell function in the SAVOR-TIMI 53 study.
Leibowitz G; Cahn A; Bhatt DL; Hirshberg B; Mosenzon O; Wei C; Jermendy G; Sheu WH; Sendon JL; Im K; Braunwald E; Scirica BM; Raz I
Diabetes Obes Metab; 2015 May; 17(5):487-94. PubMed ID: 25656169
[TBL] [Abstract][Full Text] [Related]
14. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
15. Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Yang LP
Drugs; 2012 Jan; 72(2):229-48. PubMed ID: 22221000
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
Borja-Hart NL; Whalen KL
Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
[TBL] [Abstract][Full Text] [Related]
17. The DPP-IV inhibitor saxagliptin promotes the migration and invasion of papillary thyroid carcinoma cells via the NRF2/HO1 pathway.
He L; Zhang T; Sun W; Qin Y; Wang Z; Dong W; Zhang H
Med Oncol; 2020 Oct; 37(11):97. PubMed ID: 33001278
[TBL] [Abstract][Full Text] [Related]
18. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz B
IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
[TBL] [Abstract][Full Text] [Related]
19. Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.
Pollack PS; Chadwick KD; Smith DM; Billger M; Hirshberg B; Iqbal N; Boulton DW
Cardiovasc Diabetol; 2017 Sep; 16(1):113. PubMed ID: 28903775
[TBL] [Abstract][Full Text] [Related]
20. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
